Vascular Biogenics Ltd (VBLT) Receives $3.33 Average Target Price from Brokerages

Shares of Vascular Biogenics Ltd (NASDAQ:VBLT) have been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.33.

VBLT has been the topic of several analyst reports. ValuEngine upgraded Vascular Biogenics from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Zacks Investment Research cut Vascular Biogenics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 9th.

Shares of VBLT stock traded up $0.07 during mid-day trading on Friday, hitting $1.78. 161,283 shares of the company’s stock were exchanged, compared to its average volume of 115,964. Vascular Biogenics has a fifty-two week low of $1.60 and a fifty-two week high of $9.05. The stock has a market capitalization of $50.92 million, a price-to-earnings ratio of -4.80 and a beta of -1.79.



Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings data on Thursday, May 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The firm had revenue of $0.16 million during the quarter. sell-side analysts forecast that Vascular Biogenics will post -0.77 EPS for the current year.

An institutional investor recently raised its position in Vascular Biogenics stock. Raymond James & Associates increased its position in Vascular Biogenics Ltd (NASDAQ:VBLT) by 71.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 55,466 shares of the biopharmaceutical company’s stock after buying an additional 23,124 shares during the quarter. Raymond James & Associates owned about 0.19% of Vascular Biogenics worth $394,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.00% of the company’s stock.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Story: What does earnings per share mean?

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply